Drugs for Relapse Prevention of Alcoholism /
edited by Rainer Spanagel, Karl F. Mann.
- xii, 243 páginas recurso en línea.
- Milestones in Drug Therapy MDT .
Springer eBooks
History of prevention of relapse -- How to measure relapse in animals -- How to measure relapse in humans -- Disulfiram (Antabuse®): the first medication to stop drinking -- Naltrexone: preclinical data -- Naltrexone: clinical data -- Acamprosate: preclinical data -- Acamprosate: clinical data -- Serotonergic compounds: preclinical data -- Serotonergic compounds: clinical data -- Opioidergic compounds: preclinical data -- Second generation opioidergic compounds: clinical data -- Dopaminergic compounds: preclinical data -- Dopaminergic compounds: clinical data -- Baclofen: preclinical data -- Baclofen: clinical data -- Cannabinoid receptor antagonists: a perspective -- Neuropeptide Y antagonists: a perspective -- Glutamatergic compounds: a perspective -- Future perspectives on relapse prevention.
The field of biomedical research on alcoholism has developed at an astonishing speed in recent years. Today, new medications and treatment strategies are available and new leads are currently tested in multi-center trials. This book gives a comprehensive overview about different neurotransmitter/peptide systems involved in craving and relapse behavior and critically describes the clinical application of new anti-craving and anti-relapse compounds. The editors - a preclinical researcher and a clinical researcher, together with some of the most distinguished experts in the field - compiled the most recent available preclinical and clinical data, offering a thorough picture on modern relapse prevention. Undoubtedly, this book sets out to provide an all-encompassing overview about the topic, which will be of interest to the preclinical researcher, the clinician as well as to the patient who wants to learn more.